Compare APD & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APD | GSK |
|---|---|---|
| Founded | 1940 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.3B | 100.0B |
| IPO Year | 1994 | 2013 |
| Metric | APD | GSK |
|---|---|---|
| Price | $272.70 | $47.23 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 8 |
| Target Price | ★ $345.11 | $59.58 |
| AVG Volume (30 Days) | 917.9K | ★ 2.5M |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | 2.60% | ★ 3.71% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,037,300,000.00 | N/A |
| Revenue This Year | $5.96 | $3.84 |
| Revenue Next Year | $5.80 | $4.65 |
| P/E Ratio | ★ N/A | $32.75 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $229.11 | $42.85 |
| 52 Week High | $314.87 | $61.70 |
| Indicator | APD | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 26.92 | 38.32 |
| Support Level | $255.27 | N/A |
| Resistance Level | $270.88 | $51.60 |
| Average True Range (ATR) | 5.11 | 0.69 |
| MACD | -1.41 | -0.13 |
| Stochastic Oscillator | 0.04 | 5.56 |
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the world's largest supplier of hydrogen and helium. It has a unique portfolio serving customers across industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated roughly $12 billion in revenue in fiscal 2025.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.